MAPT and Alzheimer disease: The employment of the SiMoA platform in measuring blood biomarkers associated with neurodegeneration [66], encompassing Aβ 42/Aβ 40, p-tau, NFL, and GFAP, has emerged as a promising approach for facilitating both the diagnosis and prognosis of AD.